Gigamune
Every clinical-stage in vivo CAR-T lentivector uses a close variant of VSV-G, so a second dose meets the immune response raised by the first.
DeepWEBSITE ↗
Why it's on the radar
TeamFundraising signals (who's likely raising, and why) are on Team.Start a free 14-day trial →Funding history · 0 rounds
No rounds on record yet.
Key people
ProKey people, exec moves and open roles are on Pro.Start a free 14-day trial →